HR In-Vitro Protein Trials 
The Pharma Data
SEPTEMBER 16, 2020
Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer. New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers.
Pfizer
AUGUST 15, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
JANUARY 27, 2023
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision.
Drug Discovery World
APRIL 11, 2024
In clonogenic assay, BRCA2-deficient DLD1 cells were ~15-fold more sensitive to FEN1 inhibition than their isogenic BRCA2-wild-type counterparts (EC50 of 350nM and 5µM, respectively), confirming the increased susceptibility of HR deficient cancer cells to FEN1 inhibition. And thanks to the city of San Diego for its hospitality.”
The Pharma Data
APRIL 23, 2021
Results of the VIALE-A study showed Venclyxto plus azacitidine significantly reduced the risk of death by 34% (overall survival; OS), compared to azacitidine alone (HR=0.66; 95% CI: 0.52, 0.85; p<0.001). Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia.
The Pharma Data
MARCH 17, 2021
The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. Overall, patient compliance for PROs was greater than 90 percent.
Pfizer
JANUARY 27, 2023
Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., It is important to note that these studies are required by U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content